Asset Details
Do you wish to reserve the book?
Fluoride Excess and Periostitis in Transplant Patients Receiving Long-Term Voriconazole Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Fluoride Excess and Periostitis in Transplant Patients Receiving Long-Term Voriconazole Therapy
Do you wish to request the book?
Fluoride Excess and Periostitis in Transplant Patients Receiving Long-Term Voriconazole Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Fluoride Excess and Periostitis in Transplant Patients Receiving Long-Term Voriconazole Therapy
2011
Overview
Background. We describe a heart transplant patient with painful periostitis and exostoses who was receiving long-term therapy with voriconazole, which is a fluoride-containing medication. Elevated plasma and bone fluoride levels were identified. Discontinuation of voriconazole therapy led to improvement in pain and reduced fluoride and alkaline phosphatase levels. Methods. To determine whether voriconazole is a cause of fluoride excess, we measured plasma fluoride levels in 10 adult post-transplant patients who had received voriconazole for at least 6 months and 10 post-transplant patients who did not receive voriconazole. To assess the effect of renal insufficiency on fluoride levels in subjects receiving voriconazole, half were recruited on the basis of a serum creatinine level of ≥1.4 mg/dL on their most recent measurement, whereas the other 5 subjects receiving voriconazole had serum creatinine levels <1.4 mg/dL. All control subjects had serum creatinine levels of ≥1.4 mg/dL. Patients were excluded from the study if they received a fluorinated pharmaceutical other than voriconazole. Results. All subjects who received voriconazole had elevated plasma fluoride levels, and no subjects in the control group had elevated levels (14.32 μmol/L ± 6.41 vs 2.54 ± 0.67 μmol/L; P<.001). Renal function was not predictive of fluoride levels. Plasma fluoride levels remained significantly higher in the voriconazole group after adjusting for calcineurin inhibitor levels and doses. Half of the voriconazole group subjects had evidence of periostitis, including exostoses in 2 patients. Discontinuation of voriconazole therapy in patients with periostitis resulted in improvement of pain and a reduction in alkaline phosphatase and fluoride levels. Conclusions. Voriconazole is associated with painful periostitis, exostoses, and fluoride excess in posttransplant patients with long-term voriconazole use.
Publisher
Oxford University Press
Subject
/ Aged
/ Alkaline Phosphatase - blood
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Antifungal Agents - adverse effects
/ Antifungal Agents - therapeutic use
/ Biological and medical sciences
/ Bones
/ Diseases of the osteoarticular system
/ Exostoses - chemically induced
/ Female
/ Heart
/ Heart Transplantation - adverse effects
/ Humans
/ Male
/ Osteoporosis. Osteomalacia. Paget disease
/ Pain
/ Periostitis - chemically induced
/ Pharmacology. Drug treatments
/ Plasma
/ Pyrimidines - adverse effects
